<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: To report the experience of the investigators and review the major treatment trials conducted for <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A MEDLINE literature review from 1970 to date was performed on the drugs prescribed for the treatment of BD </plain></SENT>
<SENT sid="2" pm="."><plain>Open and controlled clinical studies and indications for the treatment of affected organs are analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="1" ids="24261">Glucocorticoids</z:chebi> are indicated for the treatment of BD, although no controlled studies have been reported </plain></SENT>
<SENT sid="4" pm="."><plain>The combination of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> drugs is used when vital organs are involved </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="2" ids="35475">Nonsteroidal anti-inflammatory drugs</z:chebi> are of little value in <z:hpo ids='HP_0001369'>arthritis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In controlled trials, <z:chebi fb="0" ids="23359">colchicine</z:chebi> was efficacious for <z:hpo ids='HP_0010783'>erythema</z:hpo> nodosum and <z:hpo ids='HP_0001369'>arthritis</z:hpo>, particularly in women </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> A has a rapid action and when combined with <z:chebi fb="2" ids="2948">azathioprine</z:chebi> is effective in patients with severe <z:hpo ids='HP_0000554'>uveitis</z:hpo> and extraocular manifestations </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="5" ids="28830">Chlorambucil</z:chebi> is indicated for <z:hpo ids='HP_0000554'>uveitis</z:hpo> and <z:e sem="disease" ids="C0025309" disease_type="Disease or Syndrome" abbrv="">meningoencephalitis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In controlled studies, <z:chebi fb="2" ids="2948">azathioprine</z:chebi> prevented unilateral <z:hpo ids='HP_0000554'>uveitis</z:hpo> from becoming bilateral and improved extraocular symptoms </plain></SENT>
<SENT sid="10" pm="."><plain>Pulse <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> combined with <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> improves severe systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Interferon alpha benefits ocular and extraocular manifestations, but controlled studies are lacking </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="44185">Methotrexate</z:chebi> is indicated for <z:hpo ids='HP_0000554'>uveitis</z:hpo> and <z:hpo ids='HP_0001369'>arthritis</z:hpo>, and <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> improves gastrointestinal <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>In controlled trials, thalidomide was effective for mucocutaneous manifestations, but on its discontinuation the disease exacerbated </plain></SENT>
<SENT sid="14" pm="."><plain>Orogenital manifestations are treated with local application of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> or other medications </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: Combination therapy is not always efficacious in controlling <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="16" pm="."><plain>The goal of management is to treat early to avoid recurrences and irreversible damage to the vital organs </plain></SENT>
<SENT sid="17" pm="."><plain>With proper management of BD, loss of useful vision was reduced from 75% to 20% of the affected eyes </plain></SENT>
<SENT sid="18" pm="."><plain>However, less favorable results are seen for central <z:mp ids='MP_0008912'>nervous</z:mp> system and large artery and vein involvement </plain></SENT>
</text></document>